Upgrade to SI Premium - Free Trial

Biogen (BIIB), UCB Report Topline Results from Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

October 23, 2018 5:42 AM
Today UCB (UCB) and Biogen Inc. (NASDAQ: BIIB) announced top-line results from a Phase 2b study evaluating the safety and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles